NCT03519412
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03519412
Title Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA)
Acronym ARETHUSA
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors IFOM ETS - The AIRC Institute of Molecular Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Grande Ospedale Metropolitano Niguarda Milan Italy Details
Istituto Europeo di Oncologia Milan Italy Details
Istituto Nazionale Tumori di Milano Milan Italy Details
Istituto Clinico Humanitas Rozzano Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field